ArticleCentral European journal of urology2025
Discrepancies in volume: impact of Artemis segmented magnetic resonance imaging, ultrasound, and ExactVu measurements on prostate specific antigen density and National Comprehensive Cancer Network risk stratification.
Article in Central European journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The combination of magnetic resonance imaging (MRI) and ultrasound (US) allows for better lesion targeting and diagnostic probability compared to random prostate biopsies. The Artemis Fusion Biopsy system and ExactVu micro-US technology capitalize on this advantage and provide higher-resolution imaging of the prostate during biopsy. Their accuracy in measuring prostate volume and resulting implications on prostate specific antigen (PSA) density and risk stratification, however, has not been evaluated. We hypothesized that PSA densities as measured by these modalities will demonstrate clinically insignificant differences compared to standard measurement. Material and methods: We retrospectively reviewed all prostate fusion biopsy cases performed at our health system with Artemis or ExactVu systems from April 2021 to July 2023 and compared the PSA density calculated from the volume obtained with these systems to standard measurement with ellipsoid calculation from MRI. Change in National Comprehensive Cancer Network (NCCN) prostate cancer risk stratification was analyzed for each system. Results: Artemis MRI segmentation (0.179 ng/ml, p = 0.04) and US (0.181 ng/ml, p = 0.067) underestimated and ExactVu micro-US (0.247 ng/ml, p <0.001) overestimated PSA density. Risk stratification changed in 1.2% of Artemis MRI segmentation cases, 1.6% of Artemis US cases, and 1.2% of ExactVu micro-US cases. Conclusions: Despite differences in PSA density, choice of fusion biopsy system has minimal clinical impact on risk stratification and any of these studied systems may be used without fear of misrepresenting a patient's disease state.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.